| |
|
|
|
Xtalks, Online
2025-04-21
Small nucleic acid drugs, such as siRNA, anti-sense oligonucleotides (ASO), miRNA and aptamers, function by binding to and inhibit the activity of RNA through a process known as RNA interference (RNAi).
This class of molecules offer many advantages over traditional pharmaceuticals: unlimited target selection, high specificity, long half-life, ease of design and fast development and production processes.
In this webinar, the expert speaker will discuss recent advances in the development of small nucleic acid drugs and explain how a one-stop solution from design and synthesis to analysis, screening, verification and delivery can accelerate research.
The key topics will include:
The different modalities of small nucleic acid drugs and their latest advances
The major challenges in the development of small nucleic acid drugs and how they are being solved
Case studies demonstrating the advantages in obtaining candidates having high knockdown efficiency
Register for this webinar today to explore the latest breakthroughs in small nucleic acid drug development.
Keywords: Pharmaceutical Industry, Drug Development, miRNA, Pharmaceutical Manufacturing, Clinical Research, CRO, Cell and Gene Therapies, Cell and Gene Therapy, Basic Research, CGT, RNAi, siRNA, ASO, Small Nucleic Acid Drug
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Mark Shulewitz, PhD, Field Application Scientist – Life Science Group, GenScript Biotech Corporation
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-04-21
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|